Vanguard Capital Management
COGT icon

Vanguard Capital Management’s Cogent Biosciences COGT Stock Holding History

Vanguard Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287M Buy
7,412,330
+517,371
+8% +$18.1M 0.01% 940
2026
Q1 		$265M Buy
+6,894,959
New +$255M 0.01% 918

Other funds holding COGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Capital Management's COGT Position: Q2 2026 in Review

Vanguard Capital Management increased its Cogent Biosciences (COGT) stake by 7.5% in Q2 2026, buying an estimated $18.1M and bringing the position to 7,412,330 shares worth $287M. The position accounts for 0.01% of the portfolio, ranked #940.

Vanguard Capital Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Vanguard Capital Management held 7,412,330 shares of Cogent Biosciences worth $287M as of Q2 2026.
  • Vanguard Capital Management bought 517,371 Cogent Biosciences shares in Q2 2026, an estimated $18.1M.
  • Cogent Biosciences made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #940 holding.
  • Vanguard Capital Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.